Asymmetric dimethylarginine in obesity after renal transplantation.

OBJECTIVE We have assessed in obese renal transplant recipients a course of selected proinflammatory factors liable to influence the long-term outcome of transplant patients and kidney grafts. DESIGN AND PATIENTS In a prospective cohort study, we examined a total of 68 obese renal transplant recipients (body mass index [BMI] >or= 30 kg/m(2)) for a period of 12 months (Group I). A control group consisted of 72 comparable non-obese renal transplant recipients (Group II). RESULTS Significant differences were found in plasma 12 months after renal transplantation (Group I versus Group II) in asymmetric dimethylarginine (ADMA; 3.68 micromol/L +/- 0.42 micromol/L vs 2.10 micromol/L +/- 0.34 micromol/L; P < .01), adiponectin (ADPN; 15.1 microg/mL +/- 6.0 microg/mL vs 22.80 microg/mL +/- 7.2 microg/mL; P < .01), leptin (50.4 ng/L +/- 10.2 ng/L vs 22.0 ng/L +/- 8.4 ng/L; P < .01), solubile leptin receptor (ObRe; 23.6 U/mL +/- 7.4 U/mL vs 47.2 U/mL +/- 10.7 U/mL; P < .01), resistin (21.2 microg/mL +/- 10.2 microg/mL vs 15.0 microg/mL +/- 6.2 microg/mL; P < .025) and triglycerides (3.9 mmol/L +/- 1.6 mmol/L vs 2.8 mmol/L +/- 1.6 mmol/L; P < .01). There were significant correlations between ADMA and BMI (r = 0.525, P < .001), ADPN and BMI (r = -0.574, P < .001), and ADMA and ADPN in visceral fat (r = -0.510, P < .001). Correlation between ADMA and Cin was weak, but significant (r = -0.190, P < .05). CONCLUSION The results indicate that obesity after renal transplantation was associated with increased plasma ADMA and decreased ADPN in plasma and in fat tissue and may represent a risk factor for renal transplant recipients.

[1]  C. Zoccali,et al.  The enzymatic machinery for ADMA synthesis and degradation is fully expressed in human adipocytes. , 2007, Journal of nephrology.

[2]  J. Cooke,et al.  Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  C. Zoccali,et al.  ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. , 2006, Kidney international.

[4]  M. Mori,et al.  Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. , 2006, Kidney international.

[5]  P. Tsao,et al.  Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. , 2006, The Journal of clinical endocrinology and metabolism.

[6]  C. Zoccali,et al.  Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease? , 2006, Current opinion in nephrology and hypertension.

[7]  A. Fazelzadeh,et al.  Incidence of cardiovascular risk factors and complications before and after kidney transplantation. , 2006, Transplantation proceedings.

[8]  A. Soylu,et al.  Effect of obesity and overweight on cyclosporine blood levels and renal functions in renal adolescent recipients. , 2006, Transplantation proceedings.

[9]  J. Gore,et al.  Obesity and Outcome Following Renal Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  E. Çakır,et al.  Endothelial Functions Improve with Decrease in Asymmetric Dimethylarginine (ADMA) Levels after Renal Transplantation , 2005, Transplantation.

[11]  D. Nicol,et al.  Obesity is Associated with Worsening Cardiovascular Risk Factor Profiles and Proteinuria Progression in Renal Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  M. Clèries,et al.  Obesity in renal transplantation: analysis of 2691 patients. , 2005, Transplantation proceedings.

[13]  C. Hawley,et al.  Impact of obesity on renal transplant outcomes , 2005, Nephrology.

[14]  A. Sharma,et al.  Obesity, hypertension and insulin resistance , 2005, Acta Diabetologica.

[15]  M. Wolzt,et al.  Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. , 2004, The Journal of clinical endocrinology and metabolism.

[16]  T. Thum,et al.  Endogenous Nitric Oxide Synthesis Inhibitor Asymmetric Dimethyl l-Arginine Accelerates Endothelial Cell Senescence , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[17]  T. Lehtimäki,et al.  Dietary composition as a determinant of plasma asymmetric dimethylarginine in subjects with mild hypercholesterolemia. , 2004, Metabolism: clinical and experimental.

[18]  R. Jindal,et al.  Obesity and kidney transplantation. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  M. Ghoneim,et al.  WEIGHT GAIN AFTER RENAL TRANSPLANTATION IS A RISK FACTOR FOR PATIENT AND GRAFT OUTCOME , 2004, Transplantation.

[20]  J. Cooke.  Asymmetrical Dimethylarginine: The Über Marker? , 2004, Circulation.

[21]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[22]  K. Wellen,et al.  Obesity-induced inflammatory changes in adipose tissue. , 2003, The Journal of clinical investigation.

[23]  A. Hingorani,et al.  Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. , 2003, Biochemical and biophysical research communications.

[24]  W. Howell,et al.  House keeping genes and gene expression analysis in transplant recipients: a note of caution. , 2003, Transplant immunology.

[25]  T. Funahashi,et al.  Plasma adiponectin concentration before and after successful kidney transplantation. , 2003, Transplantation proceedings.

[26]  V. Teplan,et al.  Obesity and hyperhomocysteinaemia after kidney transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  H. Oflaz,et al.  The effect of calcineurin inhibitors on endothelial function in renal transplant recipients , 2003, Clinical transplantation.

[28]  G. Sesti,et al.  Weight loss in combination with physical activity improves endothelial dysfunction in human obesity. , 2003, Diabetes care.

[29]  C. Zoccali,et al.  Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. , 2003, Kidney international. Supplement.

[30]  M. Praga.  Obesity--a neglected culprit in renal disease. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  J. Chudek,et al.  The adipose tissue--a novel endocrine organ of interest to the nephrologist. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  P. Havel.  Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin , 2002, Current opinion in lipidology.

[33]  David W. Johnson,et al.  The effect of obesity on renal transplant outcomes , 2002, Transplantation.

[34]  H. Meier‐Kriesche,et al.  The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. , 2002, Transplantation.

[35]  D. Fliser,et al.  ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  A. Takeshita,et al.  Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. , 2001, Japanese circulation journal.

[37]  P. Tsao,et al.  Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. , 1999, Circulation.

[38]  J. Cooke,et al.  Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. , 1999, Circulation.

[39]  P. Stenvinkel,et al.  Adipose tissue and its relation to inflammation: the role of adipokines. , 2005, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[40]  W. Wołyniec,et al.  Mechanisms of enhanced carbohydrate and lipid metabolism in adipose tissue in uremia. , 2005, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[41]  P. Stenvinkel,et al.  Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. , 2004, Kidney international.

[42]  M. Haluzík,et al.  Adiponectin and its role in the obesity-induced insulin resistance and related complications. , 2004, Physiological research.

[43]  D. Fliser,et al.  Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[44]  S. Kihara,et al.  Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[45]  O. Schück.  Examination of Kidney Function , 1984, Developments in Nephrology.